Advertisement

Topics

Alliance Foundation Trials launches PATINA phase 3 trial of CDK 4/6 inhibitor palbociclib to treat HR+, HER2+ metastatic breast cancer

07:35 EDT 24 Aug 2017 | PharmaBiz

The Alliance Foundation Trials, LLC (AFT), in conjunction with Pfizer and six international cancer research groups, announced the launch of PATINA – a randomized, open─label, phase 3 clinical study of the cyclin─dependent kinase

Original Article: Alliance Foundation Trials launches PATINA phase 3 trial of CDK 4/6 inhibitor palbociclib to treat HR+, HER2+ metastatic breast cancer

NEXT ARTICLE

More From BioPortfolio on "Alliance Foundation Trials launches PATINA phase 3 trial of CDK 4/6 inhibitor palbociclib to treat HR+, HER2+ metastatic breast cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...